536-08-3 Usage
Description
Digallic acid is a natural polyphenolic compound that can be produced by the hydrolysis of gallotannins. It possesses antioxidant activity and exhibits inhibitory effects on reverse transcriptases from human immunodeficiency virus (HIV) and murine leukemia virus. Additionally, it inhibits calcium-activated chloride channels, blocking the initial agonist-stimulated chloride current.
Uses
Used in Pharmaceutical Industry:
Digallic acid is used as an antiviral agent for its ability to inhibit reverse transcriptases from HIV and murine leukemia virus, potentially offering therapeutic benefits in the treatment of viral infections.
Used in Neurological Applications:
Digallic acid is used as a modulator of calcium-activated chloride channels, which can help in the treatment of neurological disorders by blocking the initial agonist-stimulated chloride current.
Used in Antioxidant Applications:
Due to its antioxidant activity, digallic acid can be used as a cytoprotective agent, offering potential benefits in various health and wellness applications.
Check Digit Verification of cas no
The CAS Registry Mumber 536-08-3 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,3 and 6 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 536-08:
(5*5)+(4*3)+(3*6)+(2*0)+(1*8)=63
63 % 10 = 3
So 536-08-3 is a valid CAS Registry Number.
InChI:InChI=1/C14H10O9/c15-7-2-6(3-8(16)11(7)18)14(22)23-10-4-5(13(20)21)1-9(17)12(10)19/h1-4,15-19H,(H,20,21)
536-08-3Relevant articles and documents
COMBINATION OF COMPOUNDS DERIVED FROM GALLIC ACID FOR THE TREATMENT OF CANCER
-
, (2015/11/27)
The invention relates to a combination of compounds derived from gallic acid, with an antitumoral and antimetastatic activity via a mechanism that involves the induction of apoptosis and the immunogenic death of the tumour cells and the subsequent activation of the specific immune response. The invention also relates to a composition containing a combination of derivatives of gallic acid and pharmaceutically acceptable excipients for the production of useful medicaments in the treatment of cancer. The invention further relates to the use of said composition in a coadjuvant in conventional chemotherapy, reducing the doses of chemptherapeutic agents used in the treatment of cancer.